All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 26, 2023
Home » Blogs » BioWorld Perspectives » Yes, there’s a doctor in the House (and Senate)

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Yes, there’s a doctor in the House (and Senate)

Jan. 3, 2017
By Mari Serebrov
No Comments

Doc picIt was out with the old and in with the new Tuesday as the 114th U.S. Congress gave way to the 115th. Among the new delegates taking their seats in the House were a few more doctors, a dentist and the head of a Texas company that commercializes medical-related technologies. And the Senate welcomed a member who has done a stint as an attorney for a major hospital.

The new members won’t be a novelty in a Congress that’s already home to more than a dozen doctors, nurses, a pharmacist and other health care providers. That’s a far cry from what it was in November 2001 when Sen. John Boozman (R-Ark.), an optometrist, first took his seat in the House following a special election. At that time, only a few doctors, a dentist and a psychologist were among the congressional ranks.

With health care at the forefront of national issues, Boozman told BioWorld Today that frustration is driving health care professionals from the practice of medicine into the halls of Congress with the hope that they can make a difference for patients throughout the country. For the most part, they come from small private practices, and they have experienced first-hand how well-intended legislation and regulations play out in real life.

“I think it’s just frustration. . . . Sometimes things can sound good, but you don’t realize the unintended consequences,” Boozman said in explaining the motivation for exchanging a stethoscope for the bedlam of Congress.

As a result, health care providers have made a difference by having their voices heard in congressional committees and on the floor of the House and Senate. Many of their colleagues look to them for explanations of how the system works, as well as advice in drafting legislation on health care issues.

By serving in Congress, doctors and other providers have stopped proposals that could have had serious impacts on patients. For instance, they spoke up loudly and authoritatively when Medicare proposed a nationwide “experiment” on the reimbursement of Part B drugs that are administered in a doctor’s office. The concern that the pilot program would shutter private practices, forcing patients to have to travel longer distances to more expensive hospital-affiliated services, forced Medicare to scrap its plans, which had been slated to take effect this month.

Health care professionals also helped shape and push through the 21st Century Cures Act in the closing days of the 114th Congress. But the work isn’t done. The 115th Congress will be tasked with passing drug and device user fee agreements before Sept. 30. It will face continued pressure to increase research funding at the NIH and to dismantle the Affordable Care Act, including the medical device tax. And it will grapple with controlling health care costs, including the price of insurance and drugs.

“Drug prices are a huge issue,” Boozman said, adding that Congress needs to make sure bureaucracy isn’t adding to the cost. Malpractice reform also could help, he said. Besides increasing drug and device prices, malpractice claims have left many counties in the country with no obstetricians, the senator noted.

While such issues impact drug and device makers as much as they do providers, representatives from biopharma and med tech have yet to seek a direct role in Congress. Instead, they seem to be content to speak vicariously through lobbyists, trade associations and campaign donations. However, industry could more effectively shed light on the health care issues facing the country and shape policy if it, like the medical practice, had a few of its own serving in Congress.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 24, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 24, 2022.
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Pfizer-Seagen logos on puzzle pieces

    Pfizer to buy Seagen for $43B

    BioWorld
    Pfizer Inc.’s appetite for acquisitions shows no signs of abating as it announced this morning its plan to acquire biotech Seagen Inc. for a whopping $43 billion...
  • In war against T1D onset, Tzield-bearer Provention’s comrade Sanofi plans $2.9B takeover

    BioWorld
    Shares of Provention Bio Inc. (NASDAQ:PRVB) closed March 13 at $24.10, up $17.40, or 259%, after Wall Street learned that collaborator Sanofi SA intends to...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing